Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli

Cancer

Volumn 97, Issue 2, 2003, Pages 419-424

  Gomez, Lucia ^a,c   Garau, Javier ^a   Estrada, Cristina ^a   Marquez, Montserrat ^a   Dalmau, David ^a   Xercavins, Mariona ^b   Marti, Josep Maria ^a   Estany, Cristina ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

Ciprofloxacin prophylaxis; Ciprofloxacin resistant Escherichia coli; Leukemia

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CIPROFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACUTE LEUKEMIA; ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOOD CULTURE; CANCER PATIENT; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CONTROLLED STUDY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; GRANULOCYTOPENIA; HUMAN; LEUKEMIA; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SEPSIS;

ACUTE DISEASE; ADULT; AGED; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; NEUTROPENIA; OPPORTUNISTIC INFECTIONS;

EID: 0037439589     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11044     Document Type: Article

References (26)

1. Schimpff SC, Young VW, Greene WH, Vermeulen GD, Moody MR, Wiernik PH. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med. 1972;77:707-714.
2. Del Favero A, Menichetti F, Martino P, et al. A multicenter, double blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis. 2001;33:1295-1301.
3. Prentice HG, Hann IM, Nazareth B, Paterson P, Bhamra A, Kibbler CC. Oral ciprofloxacin plus colistin prophylaxis against bacterial infections in neutropenic patients. A strategy for the prevention of emergence of antimicrobial resistance. Br J Hematol. 2001;115:46-52.
4. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis. 1990;161:397-401.
5. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: tenth informational supplement (aerobic dilution). NCCLS document M100-S10 (m7). Wayne: National Committee for Clinical Laboratory Standards, 2000.
6. Rozenberg-Arska M, Dekker AW, Verhoef J. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment; the effect on fecal flora. J Infect Dis. 1985;152:104-107.
7. Karp JE, Merz WG, Hendricksen C, et al. Oral norfloxacin for prevention of Gram-negative bacterial infections in patients with acute leukemia and granulocytopenia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1987;106:1-7.
8. Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia: the trade-off for reduced Gram-negative sepsis. Am J Med. 1988;84:847-854.
9. Donnelly JP, Maschmeyer G, Daenen S. Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukemia-ciprofloxacin versus co-trimoxazole plus colistin. Eur J Cancer. 1992;28A:873-878.
10. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim/sulfamethoxazole and colistin. Ann Intern Med. 1987;106:7-12.
11. Martino R, Subirà M, Altés A, et al. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. Acta Haematol. 1998;99:206-211.
12. Oppenheim BA, Hartley JW, Lee W, Burnie IP. Outbreak of coagulase-negative staphylococcus highly resistant to ciprofloxacin in a leukemia unit. Br Med J. 1989;299:294-297.
13. Lew MA, Kehoe K, Ritz J, et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation. 1991;51:630-636.
14. Cruciani M, Concia E, Navarra A, et al. Prophylactic cotrimoxazole versus norfloxacin in neutropenic children: perspective randomized study. Infection. 1989;17:65-69.
15. Liang RH, Yung RW, Chan TK, et al. Ofloxacin versus cotrimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother. 1990;34:215-218.
16. Winston DJ, Ho WG, Nakao SL, Gale RP, Champlin RE. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med. 1986;80:884-890.
17. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med. 1990;88:36-42.
18. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med. 1994;330:1240-1241.
19. Kern WV, Markus A, Andriof E. Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients. Eur J Clin Microbiol Infect Dis. 1994;13:161-165.
20. Carratalà J, Fernández-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995;20:557-560.
21. Pefia C, Albareda JM, Pallarés R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother. 1995;39:520-524.
22. Hong Yoo J, Ho Huh D, Hyun Choi I. Molecular epidemiological analysis of quinolone-resistant Escherichia coli causing bacteria in neutropenic patients with leukemia in Korea. Clin Infect Dis. 1997;25:1385-1391.
23. Garau J, Xercavins M, Rodriguez-Carballeira M, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother. 1999;43:2736-2741.
24. Baum HV, Franz U, Geiss HK. Prevalence of ciprofloxacinresistant Escherichia coli in hematologic-oncologic patients. Infection. 2000;28;278-281.
25. Delarive P, Baumfartner JD, Glauser MP, Cometta A. Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies. Schweiz Med Wochenschr. 2000;130:1837-1844.
26. Madani TA. Clinical infections and blood stream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukemia. Infection. 2000;28:367-373.